MedTrace Logo

Nivolumab Combined With BMS-986253 in HCC Patients

NCT04050462 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2025-10-16

Study results available
· View outcomes & findings →

Summary

A phase II clinical trial is utilized to examine whether BMS-986253 (25 subjects) or Cabiralizumab (25 subjects) when combined with Nivolumab offers improved radiographic objective response rates (ORR) over Nivolumab monotherapy (25 subjects) in advanced HCC patients.

Conditions

Interventions

DRUG

Nivolumab 240 mg IV every 2 weeks + Cabiralizumab 4 mg/kg IV every 2 weeks

Nivolumab 240 mg IV plus Cabiralizumab 4 mg/kg IV every 2 weeks combination therapy

DRUG

Nivolumab 240 mg IV every 2 weeks + BMS-986253 1200 mg IV every 2 weeks

Nivolumab 240 mg IV plus BMS-986253 1200mg IV every 2 weeks

DRUG

Nivolumab 240 mg IV every 2 weeks

Arm 1 (control) Nivolumab 240mg IV every 2 weeks monotherapy

Sponsors & Collaborators

Principal Investigators

  • Nina Beri, MD · NYU Langone Health

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-12
Primary Completion
2025-01-31
Completion
2025-01-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04050462 on ClinicalTrials.gov